CARsgen Therapeutics Holdings Limited has announced the results of an investigator-initiated trial for CT071, an autologous CAR T-cell product targeting GPRC5D, aimed at treating newly diagnosed multiple myeloma. These research findings were presented as a poster at the 30th Annual Congress of the European Hematology Association on June 13, 2025. The company has made the announcement on a voluntary basis to inform shareholders and potential investors about this latest business update. Further details regarding the research results can be found on CARsgen's corporate website.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.